




RealRate

PHARMACEUTICAL 2021

Theravance Biopharma Inc.
Rank 284 of 409

Theravance
Biopharma 
Medicines That Make a Difference[®]



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of Theravance Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Theravance Biopharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 148% points.

The company's Economic Capital Ratio, given in the ranking table, is -253%, being 102% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	393,341
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	123,571
Liabilities, Non-Current	0
Other Assets	59,294
Other Compr. Net Income	-98
Other Expenses	36,065
Other Liabilities	0
Other Net Income	55,805
Property and Equipment	16,422
Research and Development	260,953
Revenues	71,857
Selling, General and Administrative Expense	108,661

Output Variable	Value in 1000 USD
Assets	469,057
Liabilities	123,571
Expenses	405,679
Stockholders Equity	345,486
Net Income	-278,017
Comprehensive Net Income	-278,066
Economic Capital Ratio	-253%